 |
|
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
Yong Hwan Kwon, Seong Woo Jeon, Su Youn Nam, Dong Wook Lee, Ji Hey Park, Hui Jin Bae
Korean J Intern Med. 2023;38(4):493-503. Published online 2023 Jun 28 DOI: https://doi.org/10.3904/kjim.2022.345
|
|
Citations to this article as recorded by
 Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments
Carmelo Scarpignato, Richard H. Hunt
Current Gastroenterology Reports.2024; 26(11): 273. CrossRef Efficacy and safety of tegoprazan‐ and rabeprazole‐based concomitant therapies for Helicobacter pylori infection: Real‐world evidence
Byung Wook Jung, Chan Hyuk Park, Yoon Suk Jung
Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized Controlled Multicenter Study
Han-Ning Liu, Rui Wang, Yan Cao, Feng Xian, Xian-Jin Bi, Ding-Jian Wu, Bin Wang, Xing-Wei Wang, Chun-Hui Lan
Clinical and Translational Gastroenterology.2024; 15(10): e1. CrossRef Efficacy of Tegoprazan‐Containing Sequential Eradication Treatment Compared to Esomeprazole‐Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiary Ce
Jung Won Lee, Nayoung Kim, Jongchan Lee, So Young Jo, Dong Ho Lee
Helicobacter.2024;[Epub] CrossRef
|